SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000; 284: 98492.
  • 2
    Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis [editorial]. Arthritis Rheum 2003; 48: 17714.
  • 3
    Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 3641.
  • 4
    Yelin EH, Criswell LA, Feigenbaum PG. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. JAMA 1996; 276: 104853.
  • 5
    Ward MM, Lubeck D, Leigh JP. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. J Rheumatol 1998; 25: 6419.
  • 6
    American College of Rheumatology. American College of Rheumatology's starter set of measures for quality in the care for rheumatic and musculoskeletal diseases: February 2006. 2006. URL: http://www.rheumatology.org/practice/qmc/starterset0206.asp.
  • 7
    Khanna D, Arnold EL, Pencharz JN, Grossman JM, Traina SB, Lal A, et al. Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006; 35: 21137.
  • 8
    Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academy Press; 2001.
  • 9
    American Medical Association. Consortium measures: physician consortium for performance improvement. Performance measure status report. 2008. URL: http://www.ama-assn.org/ama1/pub/upload/mm/370/measures050908.pdf.
  • 10
    Ambulatory Quality Alliance. American College of Rheumatology/American Association of Clinical Endocrinologistsmeasurement set. 2006. URL: http://www.aqaalliance.org/files/AmericanCollegeofRheumatologyProposedMeasurementset.doc.
  • 11
    National Quality Forum. Standardizing ambulatory care performance measures. 2006. URL: http://www.qualityforum.org/projects/ongoing/ambulatory/index.asp.
  • 12
    Centers for Medicare & Medicaid Services. CMS quality initiatives overview. 2004. URL: http://www.cms.hhs.gov/QualityInitiativesGenInfo/.
  • 13
    National Committee for Quality Assurance. State of health care quality 2007: disease modifying anti-rheumatic drug therapy in rheumatoid arthritis. Washington (DC): National Committee for Quality Assurance; 2007.
  • 14
    Kahn KL, MacLean CH, Wong AL, Rubenstein LZ, Liu H, Fitzpatrick DM, et al. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre–quality criteria patient cohort. Arthritis Rheum 2007; 57: 70715.
  • 15
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 92834.
  • 16
    Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 2418.
  • 17
    MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004; 51: 193202.
  • 18
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 72940.
  • 19
    Goldsmith CH, Boers M, Bombardier C, Tugwell P, for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring, and evaluation of the rheumatoid arthritis patient and trial profiles. J Rheumatol 1993; 20: 5615.
  • 20
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 21
    Joint Working Group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. Guidelines and audit measures for the specialist supervision of patients with rheumatoid arthritis: report of a Joint Working Group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 1992; 26: 7682.
  • 22
    Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 23
    Wells G, Haguenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for treating rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 24
    Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 25
    Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, et al. Injectable gold for rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 26
    Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for treating rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 27
    Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for treating rheumatoid arthritis In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 28
    Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for treating rheumatoid arthritis. In: Cochrane library. 2nd ed. Oxford: Update Software; 2001.
  • 29
    Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 30
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 31
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 32
    MacLean CH, Bulpitt KJ, Clements PJ, Grossman JM, Suarez-Almazor M, Traina SB, et al. The effects of DMARDs on radiographic progression in RA: a systematic review [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S78.
  • 33
    Furst D, Koehnke R, Burmeister L, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis, J Rheumatol 1989; 16: 31320.
  • 34
    Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001; 30: 13542.
  • 35
    Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis 1993; 52: 7115.
  • 36
    Haagsma CJ, Russel FG, Vree TB, van Riel PL, van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996; 42: 195200.
  • 37
    Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 8690.
  • 38
    Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998; 37: 6129.
  • 39
    Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994; 37: 148791.
  • 40
    Suarez-Almazor M, Foster W. Effects of disease modifying antirheumatic drugs (DMARDs). Clin Evid 2001; 6: 92744.
  • 41
    St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 343243.
  • 42
    Khanna D, Paulus HE. Corticosteroids. In: HayesBF, PisetskyDS, ClairEW, editors. RA textbook of rheumatology. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 283302.
  • 43
    Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for RA. In: Cochrane library. Oxford: Update Software; 1998. p. 121.
  • 44
    Gotzsche PC, Johansen HK. Short-term, low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. In: Cochrane library. Oxford: Update Software; 1997. p. 119.
  • 45
    A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis: report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH, and Other Therapeutic Measures in Chronic Rheumatic Diseases. Ann Rheum Dis 1959; 18: 17388.
  • 46
    A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis: a second report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH, and Other Therapeutic Measures in Chronic Rheumatic Diseases. Ann Rheum Dis 1960; 19: 3317.
  • 47
    Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136: 112.
  • 48
    Saag KG. Glucocorticoid therapy in rheumatoid arthritis. In: Modern therapeutics in rheumatic diseases. Totowa (NJ): Humana Press; 2001.
  • 49
    Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 31628.
  • 50
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse HA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 91620.
  • 51
    Cush JJ. Global arthritis score: a rapid practice tool for rheumatoid arthritis (RA) assessment [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S686.
  • 52
    Yazici Y. Monitoring response to treatment in rheumatoid arthritis: which tool is best suited for routine “real world” care? Bull NYU Hosp Jt Dis 2007; 65: 258.